Clinipace Worldwide Appoints Nikolas Burlew To Head Up New RSD Global Consulting Group

MORRISVILLE, N.C., Aug. 07, 2017 (GLOBE NEWSWIRE) -- Clinipace Worldwide, a global full-service clinical research organization (CRO), has appointed Nikolas Burlew as Executive Vice President, RSD Global Consulting. Burlew will head up Clinipace’s newly launched RSD Global Consulting Group (RSDGC), providing strategic consulting and regulatory support in the United States, Europe, and Asia Pacific. Clinipace RSDGC provides stage-specific solutions for all phases of development, from non-clinical and clinical, through to marketing applications and post-marketing support.

Burlew – who has been in senior leadership positions within the Regulatory and Strategic Development Group at Clinipace since March 2011 – has 25+ years of experience in drug development, manufacturing and quality assurance. In his new role, he will oversee all elements of the RSD Global Consulting Group, including strategy, finances, business development and human resources.

“I am excited to launch this new consulting offering, which I believe will meet customer needs as part of our full-service approach,” said Nikolas Burlew, who was recently appointed Executive Vice President, RSD Global Consulting, at Clinipace. “Our strategic and regulatory support can reduce development timelines by ensuring that sound decisions are made at every step.”

“Warmest congratulations to Nikolas Burlew on this well-deserved promotion,” said Clinipace President and CEO Jeff Williams. “Nikolas’ depth of experience will drive this new offering, ensuring that Clinipace continues to be the careful steward of our clients’ therapeutic programs, managing costs, quality, and deliverables to help ensure each organization’s goals are met.”

Prior to joining Clinipace, Burlew held positions with Regulus Pharmaceutical Consulting, Sandoz, NaPro BioTherapeutics, and Synergen. He has a BA in Biology from the University of Colorado Boulder.

About Clinipace Worldwide
Clinipace Worldwide, a global full-service clinical research organization (CRO) serves the unique needs of venture-backed, mid-tier and strategic pharmaceutical, biotechnology and medical device firms, helping them advance drug candidates to deliver successful stakeholder and patient outcomes. The company leverages extensive therapeutic knowledge, clinical trial expertise, and their proprietary eClinical platform TEMPO™ to support life science firms in achieving some of their most important goals: Executing regulatory strategies, optimizing clinical development timelines and completing high quality trials.

Clinipace has completed more than 1,500 clinical trials and 1,500 regulatory and statistical consulting projects and operates in North America, South American, Europe, and Asia. To learn more, visit

Media Contact Sandra Parrish Woodlief 919-797-9480;

Source: Clinipace Worldwide